Fusion Pharmaceuticals Inc 's ROA from the first quarter of 2024 to the first quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Fusion Pharmaceuticals Inc 's ROA in the first quarter of 2024?
Fusion Pharmaceuticals Inc recorded a cumulative net loss of $-104 million during 12 months ending in the first quarter of 2024, resulting in a negative return on assets (ROA) of -37.23%.

However, within the Healthcare sector 533 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2024 quarter, so far to 4126, from total ROA ranking in the fourth quarter of 2023 at 4720.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter	(Mar 31 2023) I. Quarter
Y / Y Total Assets Change	22.5 %	31.96 %	5.95 %	17.47 %	11.5 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-104	-95	-91	-98	-92
Return On Assets (TTM)	-37.23 %	-35.77 %	-36.82 %	-40.11 %	-39.2 %
FUSN's Total Ranking	# 4126	# 4720	# 4240	# 4387	# 4502
Total Assets (TTM) in million	321	286	249	265	262
Seq. Total Assets Change	12.44 %	14.84 %	-6.16 %	1.1 %	21.13 %
Seq. Net Income Change	-	-	-	-	-

FUSN's 5 Years Annual ROA >> Back to FUSN Management Effectiveness >> Compare FUSN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 70
Sector	# 534
Overall	# 4055

Return On Assets Statistics
High	Average	Low
-22.55 %	-32.73 %	-39.54 %
(Jun 30 2021)		(Jun 30 2023)

Financial Statements
Fusion Pharmaceuticals Inc 's Assets	$ 321 million	FUSN's Balance sheet
Fusion Pharmaceuticals Inc 's Income	$ -34 million	Quarterly FUSN's Income Statement
FUSN's Income by Division		See FUSN's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	FY
Y / Y Total Assets Change	30.98 %	-14.22 %	-18.68 %	-	-
Total Assets in million	283	216	252	310	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-95	88	-81	-78	0
Annual Return On Assets	-33.48 %	40.49 %	-32.13 %	-25.25 %	-

FUSN's 5 Years Annual ROA >> Back to FUSN Management Effectiveness >> Compare FUSN ROA to its Competitors

More Return On Assets Ratios
FUSN's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
FUSN's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for FUSN's Competitors
Subscribers only: Roa for Fusion Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for FUSN's Customers

You may also want to know
FUSN's Roi	FUSN's Inventory Turnover Ratio	FUSN's Growth Rates	FUSN's Dividend Comparisons
	FUSN's Profitability Ratios	FUSN's Asset Turnover Ratio	FUSN's Dividend Growth
FUSN's Roe	FUSN's Valuation Ratios	FUSN's Financial Strength Ratios	FUSN's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2024, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:22:13+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.